**INTRODUCTION**

The term “aphthous” is derived from a Greek word “aphtha” which means ulceration. Recurrent aphthous stomatitis (RAS) is one of the most common painful oral mucosal conditions seen among patients. These present as recurrent, multiple, small, round, or ovoid ulcers, with circumscribed margins, having yellow or gray floors and are surrounded by erythematous haloes, present first in childhood or adolescence.\(^1\)

**CLINICAL PRESENTATION**

RAS is characterized by recurrent bouts of solitary or multiple shallow painful ulcers, at intervals of few months to few days in patients who are otherwise well.\(^2\) RAS has been described under three different clinical variants as classified by Stanley in 1972.\(^3\)

1. **Minor RAS** is also known as Miculiz’s aphthae or mild aphthous ulcers. It is the most common variant, constituting 80% of RAS. Ulcers vary from 8 to 10 mm in size. It is most commonly seen in the nonkeratinized mucosal surfaces like labial mucosa, buccal mucosa, and floor of the mouth. Ulcers heal within 10–14 days without scarring.

2. **Major RAS** is also known as periadenitis mucosa necrotica recurrens or Sutton’s disease. It affects about 10–15% of patients. Ulcers exceed 1 cm in diameter. Most common sites of involvement are lips, soft palate, and fauces. Masticatory mucosa like dorsum of tongue or gingiva may be occasionally involved.\(^4\) The ulcers persist for up to 6 weeks and heal with scarring.

3. **Herpetiform ulceration** is characterized by recurrent crops of multiple ulcers; may be up to 100 in number. These are small in size, measure 2–3 mm in diameter. Lesions may coalesce to form large irregular ulcers. These ulcers last for about 10–14 days. Unlike herpetic ulcers, these are not preceded by vesicles and do not contain viral infected cells. These are more common in women and have a later age of onset than other clinical variants of RAS.\(^5\)

**Predisposing factors**

**Genetics**

A genetic predisposition for the development of apthous ulcer is strongly suggested as about 40% of patients have a family history and these individuals develop ulcers earlier and are of more severe nature.\(^2\) Various associations with HLA antigens and RAS have been reported. These associations vary with specific racial and ethnic origins.

**Trauma**

Trauma to the oral mucosa due to local anesthetic injections, sharp tooth, dental treatments, and tooth brush injury may predispose to the development of recurrent aphthous ulceration (RAU).\(^11\) Wray et al.\(^6\) in 1981 proposed that mechanical injury may aid in identifying and studying patients prone to aphthous stomatitis.

**Tobacco**

Several studies reveal negative association between cigarette smoking, smokeless tobacco and RAS. Possible explanations given include increased mucosal keratinization; which serves as a mechanical and protective barrier against trauma and microbes.\(^7-9\) Nicotine is considered to be the protective factor as it stimulates the production of adrenal steroids by its action on the hypothalamic adrenal axis and reduces production of tumor necrosis factor alpha (TNF-α) and interleukins 1 and 6 (IL-1 and IL-6).\(^10\) Nicotine replacement therapy has been suggested as treatment for patients who develop RAU on cessation of smoking.\(^11\)
Drugs
Certain drugs have been associated with development of RAU; these include angiotensin converting enzyme inhibitor captopril, gold salts, nicorandil, phenindione, phenobarbital, and sodium hypochloride. NSAIDS such as propionic acid, diclofenac, and piroxicam may also cause oral ulceration similar to RAS.[12]

Hematocytic deficiency
Deficiencies of iron, vitamin B12, and folic acid predispose development of RAS. Deficiencies of these hematocytics are twice more common in these individuals than controls. Contrary findings in various studies relating the association of hematocytic deficiency and RAS have been explained as due to varying genetic backgrounds and dietary habits of the study population.[2,12]

Gluten sensitive enteropathy/celiac disease, inflammatory bowel disease
Gluten sensitive enteropathy (GSE) is an autoimmune inflammatory disease of small intestine that is precipitated by the ingestion of gluten, a wheat protein in susceptible individuals. It is characterized by severe malnutrition, anemia, abdominal pain, diarrhea, aphthous oral ulcers, glossitis, and stomatitis. RAS may be the sole manifestation of the disease. The use of gluten-free diet in the improvement of RAS is considered uncertain. It has been suggested that evaluation for celiac disease may be appropriate for RAS patients.[11] Inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis may present with aphthous-like ulceration.[1]

Sodium lauryl sulfate - containing toothpaste
An increased frequency in the occurrence of RAS has been reported on using sodium lauryl sulfate (SLS)-containing toothpaste with some reduction in ulceration on use of SLS-free tooth paste. However, because of the widespread use of SLS-containing dentifrice, it has been proposed that this may not truly predispose to RAS.[6]

Hormonal changes
Conflicting reports exist regarding association of hormonal changes in women and RAU. Studies state association of oral ulceration with onset of menstruation or in the luteal phase of the menstrual cycle. Mc Cartan et al.[14] in 1992 established no association between aphthous stomatitis and premenstrual period, pregnancy, or menopause.

Stress
Stress has been emphasized as a causative factor in RAU. It has been proposed that stress may induce trauma to oral soft tissues by parafunctional habits such as lip or cheek biting and this trauma may predispose to ulceration. A more recent study shows lack of direct correlation between levels of stress and severity of RAS episodes and suggests that psychological stress may act as a triggering or modifying factor rather than etiological factor in susceptible RAS patients.[15]

Micro organisms implicated in aphthous ulcers
Several micro organisms have been implicated in the pathogenesis of RAS. Several contrary findings have been reported in the various studies published.

RAS and oral streptococci
Oral streptococci have been considered as microbial agents in the pathogenesis of RAS. They have been implicated as microorganisms directly involved in the pathogenesis of these lesions or as agents which serve as antigenic stimuli, which in turn provoke antibody production that cross-react with oral mucosa. It has been suggested that L form of α-hemolytic streptococci, Streptococcus sanguis; later identified as Streptococcus mitis was the causative agent of this disease. Hoover et al.[16] in 1986 demonstrated low levels of cross-reactivity of oral Streptococci and oral mucosal antigens and considered the reactivity to be non-specific and clinically insignificant.

RAS and Helicobacter pylori
H. pylori has been implicated as one of the organisms in the etiopathogenesis of RAS. H. pylori is a gram-negative, S-shaped bacterium that has been associated with gastritis and in chronically infected duodenal ulcers. H. pylori has been reported to be present in high density in dental plaque.[17] Porter et al.[18] in 1997 measured the levels of IgG antibodies against H. pylori in patients with RAS and showed that no the frequency of anti-H. pylori seropositivity was not significantly elevated in patients with RAS and other ulcerative and non-ulcerative oral mucosal disorders.

Viruses as etiologic agents in RAS
Various viruses have been implicated in the etiopathogenesis of recurrent aphthous stomatitis. There have been several suggestive, but as yet there exists inconclusive evidence toward a viral etiology. Characteristics of aphthous ulcers which are indicative of infectious etiology include recurrent ulceration, lymphocytic infiltration, perivascular cuffing, presence of auto-antibodies, inclusion bodies in case of herpetiform ulcers indicative of infectious etiology include recurrent ulceration, lymphocytic infiltration, perivascular cuffing, presence of auto-antibodies, inclusion bodies in case of herpetiform ulcers and similarity of RAU to viral ulcerative diseases in animals.[19] Virtanen et al.[17] in 1995 demonstrated the presence of human cytomegalovirus DNA (HCMV) in biopsies of oral mucosal ulcers, but they were unable to rule out the presence of this virus which may have existed as a super infection or co infection from existing HCMV in saliva. Sun et al.[20] in 1996 demonstrated the presence of HCMV genomes by polymerase chain reaction in pre-ulcerative oral aphthous tissues. They postulated that when viral infection occurs in oral epithelial cells expressing major histocompatibility complex class II molecules (MHC-II), an intense T-cell response is elicited against virus containing oral epithelial cells. They concluded that HCMV may play role in perpetuating local immune response in genetically predisposed individuals.

Sun et al.[21] in 1998 demonstrated the presence of Epstein-barr virus (EBV) genomes by polymerase chain reaction in pre-ulcerative oral aphthous tissues in RAU patients.
They postulated a possible role of association of EBV in pre-ulcerative oral lesions in patients of RAU.

Role of tumor necrosis factor alpha in RAS

Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory cytokine and is one of the most important cytokine implied in the development of new aphthous ulcers in patients. The association of TNF-α in the development of RAS gains credence due to the fact that immunomodulatory drugs such as thalidomide and pentoxifylline have been found effective in the treatment of RAS. Thalidomide reduces activity of TNF-α by degrading its messenger RNA and pentoxifylline inhibits TNF-α production.[22,23] Antigenic stimulation of oral mucosal keratinocytes results in the production of pro-inflammatory cytokines such as IL-2 and TNF-α. TNF-α also causes expression of class I major histocompatability complex, subsequently these cells are targeted for attack by cytotoxic T cells.[1]

INDEX FOR DETERMINING IMPACT OF ORAL ULCER ACTIVITY IN PATIENTS OF RAS

Mumucu et al.[24] in 2009 proposed a composite index to monitor the clinical manifestations associated with oral ulcers in patients of RAS and Behcet’s disease. They proposed that such indices serve to provide important information regarding prognosis of disease and therapeutic effect of medication.

The index evaluated the oral ulcer activity, ulcer-related pain, and functional disability. Oral ulcer activity was recorded as number of ulcers in the past 1 month. This was scored zero if there were no ulcers and as one, if the number of ulcer was greater or equal to than one. The pain status was evaluated on a visual analogue scale (VAS). This is a 100-mm line with extreme values at either end. The patients have to mark the intensity of pain on the line.

Functional status evaluation

This involved the evaluation of effects of oral ulcers on tasting, speaking, and eating/chewing/swallowing. This was evaluated by both Likert-type scale and VAS scale. Scoring is done as 0, when none of the time; 1, little of the time; 2, some of the time; 3, most of the time; 4, all of the time and VAS (0–100 mm).

Use of visual analog scale to evaluate the pain caused by ulcers is highly subjective and is ridden with interpersonal variation. This is a continuous scale with no discrete levels as would be suggested by grades such as none, mild, moderate, or severe. Further studies in different population and ethnic groups need to be carried out using this criteria to validate this index.

HISTOPATHOLOGY OF RAS

The microscopic picture of aphthous ulcer is non-specific, and diagnosis must be based on history and careful clinical examination. The mucous membrane of aphthous ulcer shows superficial tissue necrosis with a fibrinopurulent membrane covering the ulcerated area. The necrosis is covered by tissue debris and neutrophils. Epithelium is infiltrated by lymphocytes and few neutrophils. Intense inflammatory cell infiltration, predominantly neutrophils present immediately below the ulcer, mononuclear lymphocytes are seen in adjacent areas. Minor salivary glands commonly present in areas of aphthae exhibit focal periductal and perilveolar fibrosis and chronic inflammation.[12,25]

DIAGNOSIS

Diagnosis of RAS is based on history, clinical manifestations, and histopathology. Other causes of recurrent oral ulceration must be ruled out. Systemic diseases which present with recurrent oral ulcerations are summarized in Table 1. Diagnostic criteria for minor RAU were proposed by Natah et al.[12] in 2004. They proposed that a diagnosis of idiopathic RAU and secondary RAU (associated with systemic disease) is established when four major and one minor criteria are fulfilled. The major and minor criteria for diagnosis of minor RAU are illustrated in Tables 2 and 3.

Management

There is no definitive curative treatment for RAS. Possible systemic association with RAS must be ruled out, especially in cases where there is sudden development of ulceration in adulthood.[25] Laboratory investigations such as complete blood counts, red cell folate, serum ferritin levels, and vitamin B12 recommended. Screening for GSE must be done in cases where associated systemic manifestations of GSE are present.

Table 1: Systemic diseases with recurrent oral ulceration (modified from reference 1)

| Disease                      | Presentation                                                                 |
|------------------------------|-----------------------------------------------------------------------------|
| Behcet’s syndrome            | Recurrent aphthous ulceration (RAU); ocular: Uveitis, conjunctivitis, retinitis; genital: Scrotal or penile ulcers, vaginal or vulval ulcers, perianal ulcers, epididymo-orchitis |
|                              | Dermatological: Papules, pustules, erythema nodosum-like skin lesions, cutaneous pathergy response; Arthralgias, Neural: Headaches, meningo-encephalitis |
| Magic syndrome               | Variant of Behcet’s syndrome—major aphthae and inflamed cartilage |
| PFAPA                        | Periodic fever, aphthae, pharyngitis, and cervical adenitis. Seen in young children |
| Sweet’s syndrome/acute febrile neutrophilic dermatosis | Fever, increase in PMN in peripheral blood, skin lesions: Erythematous plaques, nodules, vesicles, pustules, dense dermal neutrophilic infiltrate |
| Cyclic neutropenia           | Cyclic reduction in circulating neutrophils. Oral ulceration, cutaneous abscess, upper respiratory infections, lymphadenopathy. |
| HIV                          | Aphthous-like ulceration |
Various topical and systemic agents used in treatment of RAS are summarized in Table 4.

**CONCLUSION**

Recurrent aphthous stomatitis is a very common, recurrent painful ulceration occurring in the oral cavity. The

Table 2: Major criteria for diagnosis of RAU minor (Natah et al.[12] 2004)

| Major criteria       | Description                                                                 |
|----------------------|-----------------------------------------------------------------------------|
| Clinical appearance  | Single or multiple round/oval ulcers, shallow, regular margins, yellow-gray base, surrounded by erythematous margins. Ulcers are never preceded by vesicles. Less than 1 cm in diameter |
| Recurrence           | At least three attacks of RAU within past 3 years, ulcers do not appear in the same focal site |
| Mechanical hyperalgesia | Painful lesion, exacerbated by movement of ulcer affected area.               |
| Self-limitation of condition | Ulcer heals spontaneously without sequelae with or without treatment |

Table 3: Minor criteria for diagnosis of RAU minor

| Minor criteria                  | Description                                                                 |
|---------------------------------|-----------------------------------------------------------------------------|
| Family history of RAU           | Positive family history of RAU present                                      |
| Age of onset                    | First attack of RAU below 40 years                                          |
| Location                        | Non-keratinized oral mucosa                                                 |
| Duration                        | Ulcers lasts from few days to few weeks                                     |
| Pattern of recurrence           | Attacks triggered by hormonal changes, exposure to certain foods and drugs, intercurrent infections, stress, and local trauma |
| Histopathological examination   | Hematinic deficiency especially ferritin, folate, iron, vitamin B and zinc |
| Presence of precipitating factor | RAU patient is a non-smoker or develops ulcer after stopping smoking         |
| Presence of hematonic deficiencies | Hematinic deficiency especially ferritin, folate, iron, vitamin B and zinc |
| Negative association and smoking | Therapeutic trial with gluco-corticosteroids                                 |

Table 4: Topical and systemic agents used in treatment of RAS

| Category                       | Agent/mechanism of action                                                                 | Therapeutic effect                                                                 |
|--------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Antimicrobials                 |                                                                                           |                                                                                    |
| Chlorhexidine                  | 0.2% mouth rinse or 1% gel                                                                  | Reduces duration of ulcer                                                           |
| Triclosan                      | Anti-inflammatory agent, antimicrobial, anti-inflammatory effect as component in mouth rinses | Increase number of ulcer-free days                                                  |
| Tetracycline                   | Topical tetracycline-auromycin, chlortetracycline 5% tetracycline used as mouthwash         | Reduces number, relieves pain, shortens ulcerative phase                             |
| Penicillin G                   | 50 mg Penicillin G torches, four times a day for 4 days                                     | Reduce healing time, reduce pain                                                    |
| Steroids                       | Mouth rinses, ointment, creams. Triamcinolone acetamide-adhesive paste, betamethasone      | Effectively reduces ulcer size and alleviates ulcer pain[26]                         |
|                                | valerate-mouth rinse                                                                      | Reduce symptoms, hasten healing of RAS                                              |
| Immunomodulation               |                                                                                           |                                                                                    |
| Thalidomide                    | Inhibits production of TNF-α. Especially useful in HIV-positive patients with RAS          | Reduces number of ulcers. Has been proven to be most reliable effective agent in management of RAS. Adverse drug reaction (ADR)-teratogenic, rashes, peripheral neuropathy |
| Pentoxifylline                 | 200 mg daily for 4 weeks.                                                                  | Decrease ulcer number, reduces ulcer size, and increases ulcer-free days             |
| Colchicine                     | Reduces neutrophil phagocyte function                                                       | Reduces pain, reduces frequency of ulcers, promotes healing                          |
| Levamisole                     |                                                                                           | ADR: Diarrhea, infertility young males                                              |
| Others: Dapsone, Cimetidine     | Inhibits TNF-α, inhibits neutrophil function and chemotaxis.                              | Reduces ulcer number, pain, frequency. ADR: Nausea, dysgeusia, flu-like symptoms, rash |
|                                | 400 mg thrice daily                                                                        | Pain relief. Reduces ulcer pain, accelerates ulcer healing                           |
|                                | Inhibition of neutrophil function, chemotaxis and adhesion molecule expression              |                                                                                      |
|                                | Exact mode of action unclear                                                                |                                                                                      |
| Topical analgesics/anti-        | Mouth wash: Benzydamine hydrochloride                                                      |                                                                                      |
| inflammatory agent             | Anti-allergic and anti inflammatory                                                        |                                                                                      |
| Benzydamine                    | 5% amlexanox oral paste topical application                                                  |                                                                                      |
| Amlexanox                      |                                                                                           |                                                                                      |
| Barrier                        |                                                                                           |                                                                                      |
| Topical hyaluronic acid        | Hyaluran gel 0.2% act as a barrier                                                          | Protective barrier function helps in local tissue hydration, anti-oxidant effect[27] |
| Cyanoacrylate adhesives        | Barrier agent                                                                              | Ulcer protectant                                                                    |
| Sucralfate                     |                                                                                           | Soothing effect by adhering to the mucosal tissues                                   |
| Physical therapy               | Surgical removal                                                                           |                                                                                      |
|                                | Laser ablation                                                                            |                                                                                      |
|                                | Chemical cautery                                                                           |                                                                                      |
|                                | Low dense ultrasound                                                                      |                                                                                      |
etio-pathogenesis of this disease is yet unclear. Treatment strategies must be directed toward providing symptomatic relief by reducing pain, increasing the duration of ulcer-free periods, and accelerating ulcer healing.

REFERENCES

1. Jurge S, Kuffer R, Scully C, Porter SR. Recurrent aphthous stomatitis. Oral Dis 2006;12:1-21.
2. Scully C, Porter S. Oral mucosal disease: Recurrent aphthous stomatitis. Br J Oral Maxillofac Surg 2008;46:198-206.
3. Stanley HR. Aphthous lesions. Oral Surg Oral Med Oral Pathol Oral Radial End 1972;30:407-16.
4. Cawson RA, Odell EW. Cawson’s Essentials of Oral Pathology and Oral Medicine. 8th ed. Philadelphia: Elsevier; 2008.
5. Scully C, Porter S. Recurrent aphthous stomatitis: Current concepts of etiology, pathogenesis and management. J Oral Pathol Med 1989;18:21-7.
6. Wray D, Graykowski EA, Notkins AL. Role of mucosal injury in initiating recurrent aphthous stomatitis. Br Med J (Clin Res Ed) 1981;283:1569-70.
7. Bookman R. Relief of Canker Sores on Resumption of Cigarette Smoking. Calif Med 1960;93:235-6.
8. Shapiro S, Olson DL, Chellemi SJ. The association between smoking and aphthous ulcers. Oral Surg Oral Med Oral Pathol 1970;30:624-30.
9. Grady D, Ernster VL, Stillman L, Greenspan J. Smokeless tobacco use prevents aphthous stomatitis. Oral Surg Oral Med Oral Pathol 1992;74:463-65.
10. Floto RA, Smith KG. The vagus nerve, macrophages and nicotine. Lancet 2003;361:1069-70.
11. Scheid P, Bohadana A, Martinet Y. Nicotine patches for aphthous ulcers due to Behcet’s syndrome. N Engl J Med 2000;343:1816-17.
12. Natah SS, Konttinen YT, Enattah NS, Ashammakhi N, Sharkey KA, Häyrinen-Immonen R. Recurrent aphthous ulcers today: A review of growing knowledge. Int J Oral Maxillofac Surg 2004;33:221-34.
13. Shakeri R, Zamani F, Sotoudehmanesh R, Amiri A, Mohamadnejad M, Davatchi F, et al. Gluten sensitive enteropathy in patients with recurrent aphthous stomatitis. BMC Gastroenterol 2009;9:44.
14. McCraton BE, Sullivan A. The association of menstrual cycle, pregnancy and menopause with recurrent oral aphthous stomatitis: A review and critique. Obstet Gynecol 1992;80:455-8.
15. Gallo Cde B, Mimura MA, Sugaya NN. Psychological stress and recurrent aphthous stomatitis. Clinics (Sao Paulo) 2009;64:645-8.
16. Hoover CI, Olson JA, Greenspan JS. Humoral responses and cross reactivity to viridians streptococci in recurrent aphthous ulceration. J Dent Res 1986;65:1101-4.
17. Leimola-Virtanen R, Happonen RP, Syrjänens S. Cytomegalovirus (CMV) and Helicobacter pylori (HP) found in oral mucosal ulcers. J Oral Pathol Med 1995;24:14-7.
18. Porter SR, Barker GR, Scully C, Macfarlane G, Bain L. Serum IgG antibodies to Helicobacter pylori in patients with recurrent aphthous stomatitis and other oral disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83:325-8.
19. Hooks JJ. Possibility of a viral etiology in recurrent aphthous ulcers and Behcet’s syndrome. J Oral Pathol Med 1978;7:353-64.
20. Sun A, Chang JG, Kao CL, Liu BY, Wang JT, Chu CT, et al. Human cytomegalovirus as a potential etiologic agent in recurrent aphthous ulcers and Behcet’s disease. J Oral Pathol Med 1996;25:212-8.
21. Sun A, Chang JG, Chu CT, Liu BY, Yuan JH, Chiang CP. Preliminary evidence for an association of Epstein – Barr virus with pre- ulcerative oral lesions in patients with recurrent aphthous ulcers or Behcet’s disease. J Oral Pathol Med 1998;27:168-75.
22. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997;336:1487-93.
23. Zabel P, Schade FU, Schlaak M. Inhibition of endogeneous TNF-α formation by pentoxifylline. Immunobiology 1993;187:447-63.
24. Mumcu G, Sur H, Inanc N, Karacuylu U, Cimilli H, Sisman N, et al. A composite index for determining the impact of oral ulcer activity in Behcet’s disease and recurrent aphthous stomatitis. J Oral Pathol Med 2009;38:785-91.
25. Shafer, Hine, Levy. A Textbook of Oral Pathology. 4th ed. New Delhi: Saunders; 1997.
26. Zhou Y, Chen Q, Meng W, Jiang L, Wang Z, Liu J, et al. Evaluation of penicillin G potassium troches in the treatment of minor recurrent aphthous ulceration in a Chinese cohort: A randomized, double-blinded, placebo and no- treatment- controlled, multicenter clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109:561-6.
27. Nolan A, Bailie C, Badminton J, Rudalingam M, Seymour RA. Efficacy of topical hyaluronic acid in the management of recurrent aphthous ulceration J Oral Pathol Med 2006;35:461-5.